Summarized by Masters of Longevity from Startupticker.ch.
Clinical-stage biotech closed a USD 28 million Series B to fund trials.

Key Takeaways
- Onward Therapeutics raised about USD 28 million in Series B.
- Proceeds will fund clinical programs, manufacturing, and early R&D.
- Plans to expand Taiwan operations and pursue Taipei Exchange listing.



